Please login to the form below
simeprevir
This page shows the latest simeprevir news and features for those working in and with pharma, biotech and healthcare.
Remicade safe from biosimilar competition this year, says J&J
On the downside, hepatitis C therapy Olysio/Sovriad (simeprevir) continued its decline in the face of strong competition in the marketplace from Gilead and AbbVie, falling 86% to just $32m in
Latest news
-
2015's 'premium' prices dissuaded J&J from acquisitions, says Gorsky
to $8.1bn despite heavy competition to hepatitis C therapies Olysio (simeprevir) and Incivo (telaprevir) from Gilead and AbbVie.
-
J&J's share buyback 'doesn't prevent acquisitions'
disease and arthritis drug Remicade (infliximab) and Olysio (simeprevir) for hepatitis C virus offset by growth in newer products.
-
J&J starts to feel biosimilar competition bite
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
-
J&J signs $1bn deal with Achillion for hepatitis C therapies
J&J already has one new-generation oral HCV therapy on the market, its NS3/4A protease inhibitor Olysio (simeprevir), but could do with additional drugs in its portfolio in order
-
Harvoni sales rocket in first quarter
simeprevir), while Merck &Co also has a new treatment in the works.
More from news
Approximately 9 fully matching, plus 32 partially matching documents found.
Latest Intelligence
-
Taking a strategic approach
Meanwhile, for Olysio (simeprevir) - one of several new oral drugs that mark a major step forward in hepatitis C treatment - it was an innovative 'pay-if-you-clear' scheme that persuaded
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Medivir names new CEO
simeprevir). “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of simeprevir,” he said.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Warehousing of HCV patients reaches new high
Gilead’s interferon-free product sofosbuvir and Johnson &Johnson’s simeprevir appear to lead the field – receiving the highest levels of spontaneous and prompted awareness. ... However, Abbvie’s products ABT 267, ABT 333 and ABT 450 remain
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Roche’s Ocrevus boasts positive long-term data in MS
- Gavi says 76 wealthy countries have committed to COVAX vaccine facility
- Leadership change within Bedrock Group
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
